• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Mallinckrodt to sell Immunomedics agent

Article

Mallinckrodt Medical has acquired U.S. marketing and distributionrights to CEA-Scan, a monoclonal antibody-based imaging agentdeveloped by Immunomedics of Morris Plains, NJ. Mallinckrodt willsell CEA-Scan on a consignment basis for colorectal cancer

Mallinckrodt Medical has acquired U.S. marketing and distributionrights to CEA-Scan, a monoclonal antibody-based imaging agentdeveloped by Immunomedics of Morris Plains, NJ. Mallinckrodt willsell CEA-Scan on a consignment basis for colorectal cancer imagingin the U.S., while Immunomedics will retain manufacturing rights.

Immunomedics has been searching for a partner for CEA-Scansince its North American sales and marketing agreement with AdriaLaboratories of Dublin, OH, was terminated in 1995 after Adriawas acquired by Pharmacia (SCAN 8/16/95). St. Louis-based MallinckrodtMedical makes a nice fit, as its Dutch affiliate MallinckrodtMedical BV has licensing rights to CEA-Scan in Europe.

In other CEA-Scan news, Immunomedics reported last month thatclinical studies of the agent indicate that the product couldbe useful for detecting breast cancer. In a phase II clinicalstudy of 27 patients at the University of Miami Cancer Center,researchers found that CEA-Scan had an accuracy of 81% and a sensitivityof 89% in detecting breast lesions, as compared with surgicalbiopsy.

Immunomedics is planning to begin phase III studies of CEA-Scanfor breast cancer detection later this year. The company is awaitingfinal word from the Food and Drug Administration on its productlicense application for the use of CEA-Scan in detecting colorectalcancer (SCAN 2/28/96).

Recent Videos
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.